RxDoctor Payments Data

Anita Pandey, MD

Hematology & Oncology · Rolling Meadows, ILNPI 1245580604

Payments from drug & device makers

$9,800in general payments, 2019–2025

Across 391 payments — averaging $25.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Avyxa Pharma, LLC$1K
  • Merck$909
  • E.r. Squibb & Sons, L.L.C.$585
  • Pfizer$487
  • Genentech USA, Inc.$424
  • plus $5K from 54 others

What the payments were for

  • Speaking & faculty fees$1,00010%
  • Food & beverage$8,39886%
  • Education$4024%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis55$1,126
Avyxa Pharma, LLC1$1,000
Merck43$909
E.r. Squibb & Sons, L.L.C.27$585
Pfizer31$487
Genentech USA, Inc.16$424
AbbVie15$389
AstraZeneca18$385
Takeda Pharmaceuticals U.S.A., Inc.9$380
Bristol Myers Squibb13$311
Gilead10$280
Johnson & Johnson(2 entities)12$275
Astellas Pharma US Inc11$273
Incyte Corporation8$213
Seagen Inc.13$213
Pharmacyclics LLC, An Abbvie Company9$205
Eisai Inc.9$197
Daiichi Sankyo Inc.5$193
Servier Pharmaceuticals LLC7$148
GSK7$124
Myriad Genetic Laboratories, Inc.2$93
Tersera Therapeutics LLC3$89
Adaptive Biotechnologies Corporation3$86
G1 Therapeutics, Inc.4$84
Sanofi4$83
Puma Biotechnology, Inc.4$77
Amgen3$73
Tesaro, Inc.2$68
Immunogen, Inc.3$65
EMD Serono, Inc.3$63
Beigene USA, Inc.3$61
Tempus AI, Inc2$49
Heron Therapeutics, Inc.2$47
Karyopharm Therapeutics Inc.2$46
Mirati Therapeutics, Inc.2$42
Coherus Oncology, Inc.2$41
Agios Pharmaceuticals, Inc.2$40
Caris MPI, Inc.1$36
Jazz Pharmaceuticals Inc.2$36
Springworks Therapeutics, Inc.1$33
AMAG Pharmaceuticals, Inc.2$33
Immunocore Limited1$30
Bayer1$27
Deciphera Pharmaceuticals Inc.1$26
Array Biopharma Inc1$26
Accord Healthcare, Inc.1$25
Pharmacosmos Therapeutics Inc.1$25
Regeneron Healthcare Solutions, Inc.1$25
Foundation Medicine, Inc.1$24
Morphosys, US Inc.1$24
Blueprint Medicines Corporation1$23
Beone Medicines USA, Inc.1$23
Lilly USA, LLC1$20
Iovance Biotherapeutics, Inc.1$20
Siemens Medical Solutions USA, Inc.1$20
AVEO Pharmaceuticals, Inc.1$19
Tolmar Pharmaceuticals, Inc.1$19
Taiho Oncology, Inc.1$18
Macrogenics, Inc.1$18
Secura Bio, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,800 in reported general payments places this provider in the 50th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$3,634,493
Medicare patients
569
Services billed
169,005

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LenvimaLenvatinib Mesylate24$546,688
VerzenioAbemaciclib25$364,136
BrukinsaZanubrutinib28$362,979
TagrissoOsimertinib Mesylate19$317,290
TukysaTucatinib11$283,340
Lenalidomide19$275,070
IbrancePalbociclib14$214,543
XtandiEnzalutamide15$195,254
CalquenceAcalabrutinib Maleate14$190,322
ImbruvicaIbrutinib14$169,241
EliquisApixaban61$46,920
XareltoRivaroxaban31$34,075
Anastrozole72$1,571
Letrozole82$1,362
Dexamethasone57$1,188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Eisai Inc.Lenvima$197$546,68824 claims
AstraZenecaTagrisso, Calquence$385$507,61133 claims
Lilly USA, LLCVerzenio$20$364,13625 claims
Beigene USA, Inc.Brukinsa$61$362,97928 claims
Seagen Inc.Tukysa$213$283,34011 claims
PfizerIbrance, Eliquis$487$261,46475 claims
Astellas Pharma US IncXtandi$273$195,25415 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$205$169,24114 claims
Johnson & JohnsonXarelto$275$34,07531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 580 hematology & oncology providers in Illinois.

Other hematology & oncology in Rolling Meadows

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →